In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Avantor (AVTR – Research Report), with a price target of $29.00. The company’s shares closed yesterday at $24.40.
McNamara covers the Healthcare sector, focusing on stocks such as Illumina, QuidelOrtho, and SOPHiA GENETICS. According to TipRanks, McNamara has an average return of -10.7% and a 41.56% success rate on recommended stocks.
Avantor has an analyst consensus of Strong Buy, with a price target consensus of $25.62, which is a 5.00% upside from current levels. In a report released today, Citi also maintained a Buy rating on the stock with a $30.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $25.25 and a one-year low of $16.63. Currently, Avantor has an average volume of 6.92M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avantor (AVTR) Company Description:
Avantor, Inc. is a provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. It sells materials & consumables, equipment & instrumentation and services & specialty procurement. It operates in more than 30 countries and deliver an extensive portfolio of products and services. The company was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.
Read More on AVTR:
